peptide
Dihexa
anecdotalResearch Use OnlyOralInjection
Brain peptide originally claimed to be 10 million times more potent than BDNF for forming connections. However, the foundational paper was retracted in April 2025 after confirmed data fabrication. A clinical trial also failed all endpoints. Evidence base is now significantly weakened.
Key facts
- Classification
- Peptide — Experimental brain peptide for forming new neural connections. Limited safety data.
- Primary benefits
- Brain & Cognition (5/10) · Longevity (2/10)
- Administration
- Oral, Injection
- Doses studied
- 10-20 mg oral or 5-10 mg subq daily. Cycle for 4-8 weeks with breaks in between. NOTE: foundational research retracted in 2025 -- consider alternatives like Cerebrolysin or Semax with stronger evidence.
- Evidence strength
- Anecdotal — 14 peer-reviewed studies
- Stacks well with
- Semax, Selank, NA-Semax Amidate, SS-31
- Legal status
- Research Use Only · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Oral, Injection
- Studies referenced
- 14
- Stacks with
- 6 peptides
- Regulatory
- Research Use Only
Goal coverage · Dihexa
🧠 Brain & Cognition5/10
⏳ Longevity2/10
Medical oversight strongly recommendedNot safe during pregnancy· 4 contraindications